View Older Stories View More Recent Stories

Jan 9, 2025 07:00AM Arkuda Therapeutics Announces Option Exercise and Asset Purchase
Jan 8, 2025 09:00AM Actio Biosciences Expands Leadership Team with Appointment of Cayce Denton as Chief Financial Officer
Jan 7, 2025 09:00AM Be Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Dec 11, 2024 07:00AM Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio, Securing $75 Million to Accelerate Genetic Medicines
Dec 8, 2024 09:00PM Be Biopharma Unveils BeCoMe-9 Trial and Presents on Versatile B Cell Medicines Platform at ASH 2024
Dec 5, 2024 11:44AM Form D Atlas Venture Fund XIV,
Dec 5, 2024 07:00AM Atlas Venture Announces $450 Million Fund XIV
Dec 3, 2024 08:00AM K36 Therapeutics Announces Multiple Poster Presentations Highlighting the First Clinical Data for KTX-1001 and Other Developmental Compounds at the 66th American Society of Hematology (ASH) Annual Mee
Nov 18, 2024 08:00AM Rectify Pharma Presents Preclinical Data Supporting Development of Lead Candidate RTY-694 at The Liver Meeting® 2024
Nov 14, 2024 04:33PM Form SC 13G/A Dyne Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Nov 14, 2024 04:32PM Form SC 13G/A Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Nov 14, 2024 04:31PM Form SC 13G/A Xilio Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Nov 14, 2024 04:30PM Form SC 13G/A Day One Biopharmaceutica Filed by: Atlas Venture Fund XI, L.P.
Nov 13, 2024 06:01AM Form 13F-HR Atlas Venture Life Scien For: Sep 30
Nov 12, 2024 08:00AM Rectify Pharma to Host Virtual R&D Event on RTY-694 for Primary Sclerosing Cholangitis and Other Hepatobiliary Diseases on November 21, 2024
Nov 12, 2024 07:00AM Trace Neuroscience Launches With $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases
Nov 5, 2024 06:27PM Form SC 13D/A Third Harmonic Bio, Inc. Filed by: Atlas Venture Fund XI, L.P.
Nov 5, 2024 04:15PM Form 4 Third Harmonic Bio, Inc. For: Nov 01 Filed by: Atlas Venture Fund XI, L.P.
Nov 5, 2024 09:05AM Be Biopharma Announces Upcoming Presentation at the 66th American Society of Hematology (ASH) Annual Meeting
Oct 31, 2024 09:45AM Form 13F-NT Atlas Venture Fund VIII, For: Sep 30
Oct 31, 2024 09:43AM Form 13F-NT Atlas Venture Associates For: Sep 30
Oct 31, 2024 09:43AM Form 13F-NT Atlas Venture Associates For: Sep 30
Oct 31, 2024 09:41AM Form 13F-HR Atlas Venture Advisors, For: Sep 30
Oct 28, 2024 06:09PM Form SC 13D/A Tectonic Therapeutic, Filed by: Atlas Venture Fund X, L.P.
Oct 22, 2024 12:00PM Be Bio Announces $82 Million Financing and Transition to Clinical Stage Company
Oct 22, 2024 07:30AM Nvelop Therapeutics to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
Oct 22, 2024 07:00AM Rectify Pharma Announces Positive Functional Modulator RTY-694 as Development Candidate for Primary Sclerosing Cholangitis
Oct 17, 2024 08:00AM Rectify Pharmaceuticals to Present New Preclinical Data at The American Association for the Study of Liver Diseases Annual Meeting
Oct 9, 2024 05:00AM Anavo Therapeutics Appoints Dr. Edward Holson as Chief Scientific Officer and President US
Oct 7, 2024 07:00AM Judo Bio Launches with $100 Million Financing to Develop Oligonucleotide Therapies Delivered to the Kidney and Appoints Rajiv Patni as CEO
Oct 2, 2024 07:00AM Triveni Bio Raises $115 Million Series B Financing to Expand Pipeline of Therapeutics Addressing Immunological and Inflammatory (I&I) Disorders
Oct 1, 2024 07:00AM Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions
Sep 30, 2024 09:00AM Be Biopharma Announces Preclinical Data for Novel Engineered B Cell Medicine for the Potential Treatment of Hypophosphatasia
Sep 27, 2024 08:04AM Lifordi Named Winner of Endpoints 11 as Developer of Antibody Drug Conjugates for Autoimmune and Inflammatory Diseases
Sep 10, 2024 03:30AM Pheon Therapeutics Expands Board with Appointment of Dr. Enoch Kariuki
Sep 10, 2024 03:00AM Sofinnova Partners appoints Karl Naegler as Partner
Sep 4, 2024 08:00AM Kinaset Therapeutics to Share Outcomes from the Phase 1 Clinical Evaluation of Frevecitinib (KN-002), an Inhaled Pan JAK Inhibitor, in Patients with Moderate to Severe Asthma and COPD via Oral Present
Sep 3, 2024 08:00AM Rectify Pharmaceuticals Appoints Pol Boudes as Chief Medical Officer
Sep 3, 2024 06:32AM Dyne Therapeutics Inc. (DYN) Appoints Doug Kerr as CMO
Sep 3, 2024 06:31AM Dyne Therapeutics Announces Key Leadership Appointments
Aug 29, 2024 06:04AM Form N-PX Atlas Venture Life Scien For: Jun 30
Aug 21, 2024 06:00AM Non-Executive Director Appointment
Aug 9, 2024 06:05AM Form 13F-HR Atlas Venture Life Scien For: Jun 30
Aug 5, 2024 09:23AM Form 13F-NT Atlas Venture Fund VIII, For: Jun 30
Aug 5, 2024 09:23AM Form 13F-HR Atlas Venture Advisors, For: Jun 30
Aug 5, 2024 09:22AM Form 13F-NT Atlas Venture Associates For: Jun 30
Aug 5, 2024 09:22AM Form 13F-NT Atlas Venture Associates For: Jun 30
Jul 30, 2024 08:00AM BioIVT Appoints Dr. Judith Dunn and Dr. Auro Nair to its Board of Directors
Jul 19, 2024 06:50AM GRO Biosciences Closes $60M Series B Financing Co-Led by Atlas Venture and Access Biotechnology
Jul 16, 2024 08:00AM Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline
View More Recent Stories View Older Stories